Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts, valuing the company at over ₹1,500 crore. Backed by Eight Roads, FIL Capital and F-Prime, PlasmaGen has raised over ₹600 crore to date and operates one of India’s five plasma fractionation facilities near Bengaluru.